Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $33.62 Consensus Target Price from Analysts

Key Points

• Denali Therapeutics Inc. has received a consensus recommendation of "Buy" from seventeen analysts, with an average twelve-month price target of $33.62.
• Insider trading activity has seen significant sales, with insiders selling a total of 501,962 shares valued at approximately $7.5 million over the last 90 days.
• The company reported an EPS of ($0.72) for the last quarter, beating the consensus estimate of ($0.74), while analysts anticipate posting -2.71 EPS for the current year.

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have earned an average recommendation of "Buy" from the seventeen analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, thirteen have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $33.6154.

Several research analysts have recently weighed in on the company. Morgan Stanley lowered their target price on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a report on Monday, August 18th. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Bank of America lowered their target price on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Robert W. Baird lowered their target price on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Finally, HC Wainwright lowered their target price on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th.

Denali Therapeutics Price Performance

NASDAQ:DNLI traded up $0.05 during trading hours on Friday, hitting $15.65. 1,555,954 shares of the stock were exchanged, compared to its average volume of 1,802,434. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $33.33. The firm's fifty day moving average price is $14.42 and its 200 day moving average price is $14.90. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. The company has a market cap of $2.29 billion, a P/E ratio of -5.59 and a beta of 1.36.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same period last year, the firm earned ($0.59) EPS. As a group, equities research analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,937 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider directly owned 242,346 shares in the company, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ryan J. Watts sold 495,282 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the transaction, the chief executive officer owned 253,071 shares in the company, valued at $3,796,065. This represents a 66.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 501,962 shares of company stock worth $7,520,799. Insiders own 12.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Denali Therapeutics by 15.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company's stock valued at $79,000 after acquiring an additional 753 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Denali Therapeutics by 7.4% in the second quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company's stock valued at $189,000 after purchasing an additional 930 shares during the period. Knights of Columbus Asset Advisors LLC raised its position in Denali Therapeutics by 2.7% in the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock valued at $548,000 after purchasing an additional 1,058 shares during the period. Sterling Capital Management LLC raised its position in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. Finally, E Fund Management Co. Ltd. raised its position in Denali Therapeutics by 12.8% in the second quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company's stock valued at $190,000 after purchasing an additional 1,543 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.